The Pharma Data

APRIL 1, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has completed the asset transfer associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited (“Teijin Pharma”) for JPY 133.0 billion 1.? This asset transfer agreement was announced in February 2021.

Production 52

Production Pharmaceutical Companies Therapies Marketing 52

Eye on FDA

NOVEMBER 9, 2023

That brings the total number of letters issued by OPDP to five this year – one Warning Letter that came out in August respecting a sales aid used in promoting a treatment for COPD, and 4 untitled letters – one in June, one in August, and now two in October. There was no concentration among products with boxed warnings.

FDA 88

FDA Pharmaceutical Companies Production Pharmaceuticals 88

The Pharma Data

MARCH 26, 2021

Despite continuous innovations in the treatment landscape, unmet needs remain. Overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation. vs. 9.4%), nasopharyngitis (19.3%

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

The Pharma Data

MARCH 13, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for lanadelumab subcutaneous injection, a monoclonal antibody therapy for prophylaxis against attacks of hereditary angioedema (HAE).

Treatment 52

Treatment Pharmacokinetics Drugs Production 52

DrugBank

SEPTEMBER 19, 2024

Oral drug delivery remains the gold standard in pharmaceutical administration. It offers convenience for patients, promotes medication adherence, and improves treatment outcomes. This could aid in treatment for diabetic patients who currently rely on injections. This knowledge is instrumental in optimizing treatment plans.

Pharmacokinetics 98

Pharmacokinetics Drugs Treatment Disease 98

The Pharma Data

APRIL 19, 2022

Food and Drug Administration (“FDA”) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia. Teva Pharmaceutical Industries Ltd. as quickly as possible. About Teva.

Pharmaceutical Companies 52

Pharmaceutical Companies Compliance Biosimilars Pharmaceuticals 52

Drug Target Review

DECEMBER 11, 2024

Purity and radioactive enrichment are key factors in ensuring the IS aligns with product specifications. However, this method isn’t universally applicable, as some matrices may not be compatible with charcoal treatment due to their specific composition or the nature of the analytes involved.

International 52

International Laboratories Drugs Pharmacokinetics 52

Altus Drug Development

JUNE 30, 2022

A focus on customers has always been one of the main pillars of the pharmaceutical industry. However, this is often narrowed down to the creation of product-centric marketing strategies with a strong customer orientation. The onset of the covid-19 pandemic has caused considerable strain on the pharmaceutical industry as a whole.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Production 52

Pharmaceutical Development Group

AUGUST 9, 2021

Nowadays, as the usage of medicines is increasing, pharmaceutical companies are more eager to bring manufacturing a new look in quality and performance. It involves designing, analyzing, and controlling manufacturing by taking timely measurements to ensure final product quality, efficacy, and safety.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies FDA Approval Production 52

Conversations in Drug Development Trends

MAY 14, 2024

.” It’s about understanding a trial’s individual components—the research objectives, the biology of the disease, the specific needs of the patient population, regional treatment options, the current competitive landscape—and then building a customized, informed solution. Patients are at the core of everything we do.

Disease 81

Disease Clinical Trials Trials Pharmaceutical Companies 81

The Pharma Data

AUGUST 31, 2020

Company working to ensure broad Canadian access to COVID-19 vaccine candidate, following approval from Health Canada. one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has agreed in principle to supply the Government of Canada with doses of its SARS-CoV-2 vaccine candidate, Ad26.COV2.S.

Government 52

Government Vaccine Pharmaceutical Companies Clinical Trials 52

The Pharma Data

DECEMBER 29, 2020

NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs 75

Drugs Small Molecule Production Disease 75

Altus Drug Development

JUNE 28, 2022

Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine? To comply with the law.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Doctors Treatment 52

The Pharma Data

NOVEMBER 30, 2020

01, 2020 (GLOBE NEWSWIRE) — TearClear , an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development. BOSTON, Dec.

FDA 52

FDA Pharmaceutical Companies Compliance Pharmaceuticals 52

DrugBank

DECEMBER 18, 2024

DTx interventions include sensor-equipped wearable devices, remote patient monitoring tools, and virtual reality platforms integrated with conventional pharmaceutical treatments.   Empowering Patients and Enhancing Outcomes A cornerstone of treatment success lies in patient engagement and treatment adherence.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Treatment Therapies 52

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

APRIL 1, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Orifarm Group (“Orifarm”) for a total value of up to $670 million USD. This divestment agreement was first announced in April 2020.

Pharmaceutical Companies 52

Pharmaceutical Companies Production Pharmaceuticals Treatment 52

KIF1A

JULY 1, 2023

Read the Pre-print Rare Roundup A seemingly small semantic issue is a major roadblock to develop treatments for rare diseases We’ve spoken often about the goal of repurposing existing drugs to better treat KAND – this is a reality for many families who utilize off-label prescriptions. * What’s a pre-print?

Small Molecule 98

Small Molecule FDA Approval Disease Pharmaceutical Companies 98

Drug Target Review

JUNE 19, 2024

Also, many companies never reached the point where they received validation from big pharmaceutical companies. Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. Could you give us an overview of the Lineage platform?

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

The Pharma Data

NOVEMBER 11, 2020

Lung Tx will receive an upfront payment, milestone, and royalty payments based on product sales. There currently are no approved drug treatment options for this condition. Currently, the only approved treatments for an LPE are interventions such as chest tube drainage, and if unsuccessful, a surgical procedure.

Licensing 40

Licensing Licensing Treatment Pharma Companies 40

The Pharma Data

APRIL 1, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio. Soticlestat (TAK-935): Novel MoA for Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.

Marketing 52

Marketing Pharmaceutical Companies Production Treatment 52

The Pharma Data

SEPTEMBER 3, 2020

The pre-clinical studies were conducted by researchers from Beth Israel Deaconess Medical Center (BIDMC) in collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson and others as part of its ongoing collaboration to accelerate the development of a SARS-CoV-2 vaccine. Source link.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

The Pharma Data

MARCH 15, 2022

Teva is donating medicines valued at over $11M, for acute therapies in support of Ukrainian refugees The donations include over 1 million packages of antibiotics and other essential medicines as well as hygienic products for Ukrainian infants and children. Teva Pharmaceutical Industries Ltd. The donations made by Teva include over 1.3

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Packaging Therapies 52

The Premier Consulting Blog

MAY 17, 2023

It is an unfortunate reality that many diseases and conditions affect such small numbers of patients that, when a sponsor develops a drug or biological product to treat them, relatively little return on investment is generated to offset the high development costs.

Drugs 52

Drugs Disease Production Clinical Trials 52

The Pharma Data

AUGUST 5, 2020

Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators. August 05, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. We are scaling up production in the U.S.

Government 52

Government Vaccine Pharmaceutical Companies Pharmaceuticals 52

The Pharma Data

NOVEMBER 5, 2020

and Aavis Pharmaceuticals Inc. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd. Hydroxychloroquine Sulfate Tablets are indicated for the treatment of Malaria, Lupus Erythematosus and Rheumatoid Arthritis. D/B/A Aavis Pharmaceuticals. About Jubilant Cadista Pharmaceuticals Inc.

Marketing 40

Marketing Pharmaceuticals Pharmaceutical Companies Production 40

The Pharma Data

DECEMBER 13, 2020

The Company will initiate the process to submit a supplemental New Drug Application (NDA) to the National Medical Products Administration (NMPA) in the near future. On December17 ,2018, Toripalimab obtained conditional approval from the NMPA, for the 2 nd line treatment of patients with unresectable or metastatic melanoma.

Treatment 40

Treatment Clinical Trials Biosimilars Pharmaceutical Companies 40

The Pharma Data

JANUARY 3, 2021

04, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that its subsidiary, InspirMed Inc., SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Disease 52

The Pharma Data

JANUARY 6, 2021

The data come from 46brooklyn Research, a nonprofit company that aims to improve access to drug pricing information. AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Pfizer, and other major pharmaceutical companies are raising their prices by a median of 4.6 1, company spokesperson Lyndsay Meyer told CBS News.

Drugs 52

Drugs Pharmaceutical Companies Pharmaceuticals Treatment 52

DrugBank

JANUARY 22, 2025

Environmental Impacts of Traditional Pharmaceutical Production Traditional pharmaceutical manufacturing is complex, with each phase contributing to environmental degradation. The extraction and synthesis of active pharmaceutical ingredients (API) utilize vast amounts of water and energy.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Production Government 52

The Pharma Data

DECEMBER 17, 2020

The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product. Our mission is to empower precision medicine at the local level.

Laboratories 52

Laboratories Pharmaceutical Companies Production RNA 52

The Pharma Data

NOVEMBER 29, 2020

(Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ?-synuclein synuclein for the potential treatment of synucleinopathies including Parkinson’s disease and dementia with Lewy bodies.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

The Pharma Data

JANUARY 6, 2021

Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients. No other terms were disclosed.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JUNE 25, 2021

protofibril antibody for the treatment of Alzheimer’s disease (AD). 1 The proof-of-concept Study 201 explored the impact of treatment with lecanemab on reducing brain amyloid beta (A?) There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.

Disease 40

Disease Treatment Therapies FDA 40

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

DECEMBER 14, 2020

DetermaRx is a treatment stratification test that identifies stage I-IIA non-squamous NSCLC patients at high-risk of recurrence despite ostensibly curative surgery, who may benefit from the addition of chemotherapy. “We Management of such patients depends on prognostic staging to identify the individuals most likely to have occult disease.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52